Allergies
Drug research and approvals for allergies: what is recruiting, what Health Canada authorized, FDA orphan designations and EU medicines. See every condition.
As of Nov 16, 2026, 1,212 studies of allergies are recruiting on ClinicalTrials.gov, and Health Canada has authorized 57 drug trials for it since 2013.
- Recruiting worldwide: 1,212
- Trials authorized in Canada: 57
- FDA orphan approvals: 0
- EU medicines: 0
Recruiting Now
Newest start dates first, of 1,212 recruiting on ClinicalTrials.gov ↗- Estrogen to Improve Quality of Life for Men With Newly Diagnosed or Recurrent Metastatic Hormone Sensitive Prostate…NCT07466498 · Phase 2 · Fred Hutchinson Cancer Center · starts Dec 1, 2026
- Befotertinib Plus Chemotherapy With an MRD-guided Adaptive Strategy for Treatment Escalation and Response Optimization…NCT07709585 · Phase 2 · Guangzhou University of Traditional Chinese Medicine · starts Nov 30, 2026
- The Esophageal String Test as a Diagnostic Screening Tool for Eosinophilic Esophagitis Among Africans With Dysphagia in…NCT07027826 · Not applicable · National Institute of Allergy and Infectious Diseases (NIAID) · starts Nov 19, 2026
- Evaluating the Safety and Tolerability of Baricitinib in Patients With Job Syndrome With Lupus-Like Disease and/or…NCT07262983 · Phase 1 · National Institute of Allergy and Infectious Diseases (NIAID) · starts Nov 19, 2026
- Digital Mindfulness Meditation in Adolescents With Atopic DermatitisNCT07746427 · Not applicable · Weill Medical College of Cornell University · starts Nov 15, 2026
- Light Bulb Stimuli to Reduce Chronic PainNCT07825792 · Not applicable · University of North Carolina, Chapel Hill · starts Nov 9, 2026
- Feasibility, Acceptability, and Safety Trial of Brief, Breath Control-Focused Acceptance and Commitment Therapy in…NCT07566117 · Not applicable · University of North Carolina, Chapel Hill · starts Nov 9, 2026
- Non-inferiority Study of a Hydroxyapatite and Calcium Hypophosphite Toothpaste Compared With Two Comparator Toothpastes…NCT07939620 · Not applicable · Dr. August Wolff GmbH & Co. KG Arzneimittel · starts Nov 9, 2026
- A Clinical Trial of Tulisokibart (MK-7240) in Participants With Pulmonary Sarcoidosis (MK-7240-016)NCT07867938 · Phase 2 · Merck Sharp & Dohme LLC · starts Nov 3, 2026
- Zileuton for Food AllergyNCT07935616 · Phase 1 · Abigail Lang · starts Nov 3, 2026
Trials Authorized in Canada
The 10 newest of 57; search them all in Canada trials| Sep 18, 2026 | A 52-week multicenter, randomized, double-blind, placebo-controlled study to assess efficacy and safety of remibrutinib (lou064) in adult and adolescent…REMIBRUTINIB (LOU064) / ALK 762 PEANUT | Novartis Pharmaceuticals Corporation | Pending |
| Aug 19, 2026 | Investigating nasal and ocular immune response to conjunctival allergen exposureALLERGENIC EXTRACTS STANDARDIZED GRASS POLLEN / NEGATIVE SKIN TEST CONTROL… | DR. ANNE K. ELLIS | Ongoing |
| Jun 26, 2026 | Viaskin peanut patch (dbv712) expanded access clinical trial in peanut-allergic children previously enrolled in a dbv712 clinical studyVIASKIN (DBV712) | DBV Technologies S.A. | Pending |
| May 4, 2026 | A phase 2, open label study to assess ad lib consumption of peanut in peanut allergic infants 6-through 12-months-old with epicutaneous immunotherapy with…DBV712 (VIASKIN PEANUT PATCH) | DBV Technologies S.A. | Ongoing |
| Mar 11, 2026 | An open-label, multi-center protocol for patients who have completed a previous novartis sponsored remibrutinib study and are judged by the investigator to…REMIBRUTINIB (LOU064) | Novartis Pharmaceuticals Corporation | Ongoing |
| Jun 13, 2025 | A phase 3, double-blind, placebo-controlled, randomized study to assess the safety of epicutaneous immunotherapy with dbv712 250 ¿g in 1-through 3-year old…VIASKIN PEANUT (DBV712) | DBV Technologies S.A. | Ongoing |
| May 28, 2025 | A phase 1b, open-label, exploratory study evaluating the effects of inhaled epinephrine in individuals experiencing systemic allergic reactions during allergy…EPINEPHRINE | KOKUA PHARMA INC. | Ongoing |
| Dec 20, 2024 | A phase 1, open label, single sequence, pharmacokinetic study of bbp01 (epinephrine) intranasal powder with and without nasal allergen challenge versus…EPINEPHRINE (BBP01) | BELHAVEN BIOPHARMA, INC. | Closed |
| Nov 8, 2024 | A single dose, comparative bioavailability study of epinephrine nasal spray and epinephrine intramuscular injection in allergen-challenged subjects under…EPINEPHRINE | Hikma Pharmaceuticals | Closed |
| Feb 14, 2024 | A phase 1b, open-label, exploratory study evaluating the effects of inhaled epinephrine in individuals with known or suspected metabisulfite sensitivity…EPINEPHRINE | KOKUA PHARMA INC. | Closed |
Condition names come from Health Canada's trial database. Orphan designations and EU medicines are matched when their indication names the condition as whole words, so a broader or differently worded indication can be missed. Recruiting counts are live from ClinicalTrials.gov's own condition search, refreshed daily. ClinicalTrials.gov, Health Canada Clinical Trials Database, FDA orphan designations, EMA